JAK1 and glioblastoma: Moreover, ruxolitinib directly inhibited the Janus kinase 1/2 (JAK1/2) and consequently blocked the JAK/STAT signaling pathway, thus lowering the expression of pro-proliferative, antiapoptotic, and immunosuppressive proteins and overcoming the resistance to viral replication in GBM.